Gilead Sciences Aktie
WKN: 885823 / ISIN: US3755581036
22.03.2024 15:06:14
|
Gilead Sciences Completes Acquisition Of CymaBay Therapeutics
(RTTNews) - Friday, Gilead Sciences, Inc. (GILD) announced the successful acquisition of CymaBay Therapeutics, Inc. (CBAY) for around $4.3 billion.
This acquisition involved a tender offer where the majority of CymaBay's shares were bought at $32.50 each.
Following the merger, CymaBay now operates as a fully owned subsidiary of Gilead, and CymaBay's common stock is no longer available for trading on the Nasdaq.
The acquisition is expected to strengthen Gilead's market position by broadening its portfolio with CymaBay's promising investigational lead product candidate, Seladelpar, targeted for treating primary biliary cholangitis and pruritus.
This transaction is projected to impact Gilead's GAAP and non-GAAP 2024 earnings per share by approximately $3.10 - $3.20.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Gilead Sciences Inc.mehr Nachrichten
17.10.25 |
Pluszeichen in New York: NASDAQ Composite beendet den Freitagshandel in der Gewinnzone (finanzen.at) | |
17.10.25 |
Gute Stimmung in New York: S&P 500 zum Ende des Freitagshandels mit Gewinnen (finanzen.at) | |
17.10.25 |
Freundlicher Handel in New York: NASDAQ 100 zum Ende des Freitagshandels mit Gewinnen (finanzen.at) | |
17.10.25 |
Börse New York: S&P 500 verbucht Gewinne (finanzen.at) | |
17.10.25 |
NASDAQ 100-Handel aktuell: NASDAQ 100 verbucht Zuschläge (finanzen.at) | |
17.10.25 |
Freitagshandel in New York: So performt der NASDAQ Composite aktuell (finanzen.at) | |
17.10.25 |
Börse New York: NASDAQ Composite am Freitagmittag wenig verändert (finanzen.at) | |
17.10.25 |
NASDAQ 100-Handel aktuell: NASDAQ 100 legt mittags zu (finanzen.at) |
Analysen zu Gilead Sciences Inc.mehr Analysen
Aktien in diesem Artikel
CymaBay Therapeutics Inc | 30,00 | 2,04% |
|
Gilead Sciences Inc. | 105,98 | 4,33% |
|